renoprotective effect Dexmedetomidine Cardiopulmonary Bypass Acute Kidney Injury Morbidity Mortality Renal Replacement Therapy NGAL protein,
Conditions
Interventions
Intravenous dexmedetomidine infusion after induction of anesthesia. Dexmedetomidine 0.5 mcg/kg is intravenously loaded in 20 min,
then maintained at 0.4 mcg/kg/hour throughout the operation.
The drug is clear fluid in 50 mL syringe labelled as "study drug". ,Normal saline in 50 mL syringe,
labelled as "study drug"
Experimental Drug,Placebo Comparator Drug
DEX,NSS
Sponsors
Faculty of Medicine, Chulalongkorn University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Patients undergoing elective CPB-facilitated open heart surgery 2. Age > 18 years old 3. eGFR < 60 mL/min but ≥ 30 mL/min
Exclusion criteria
Exclusion criteria: 1. Allergy to any drugs in study 2. Previous surgery in thoracic cavity 3. Severe cardiac dysfunction (LVEF 35 kg/m2
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acute Kidney Injury at surgical incision, 6 hour, 48 hour, 24 hour, 48 hour postoperatively urine NGAL | — |
Secondary
| Measure | Time frame |
|---|---|
| Length of ICU and hospital stay postoperative Counting the time spent in ICU and hospital admission,Surgical comnplicaition Postopertive describe the postoperative complication,Renal replacement therapy postoperative 24 hours describe type and time if any renal replacement thearpy required | — |
Countries
Thailand
Contacts
Public ContactToonchai Indrambarya
Faculty of Medicine, Chulalongkorn University
Outcome results
None listed